middle.news
Rhythm Biosciences turns validated diagnostics into first commercial sales
4:51pm on Tuesday 29th of September, 2026 AEST
•
Biotechnology and Medical Diagnostics
Read Story
Rhythm Biosciences turns validated diagnostics into first commercial sales
4:51pm on Tuesday 29th of September, 2026 AEST
Key Points
First commercial sales from ColoSTAT and geneType
FY2026 sales revenue of $85,339 against a $5.93 million loss
Operating cash outflow increased to $5.23 million
Cash balance rose to $3.36 million after funding activity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Rhythm Biosciences (ASX:RHY)
OPEN ARTICLE